---
title: "Earnings Preview | Pfizer Q3 Reveals TrumpRx Investment Effectiveness Facing Test After Eight Consecutive Quarters of Earnings Exceeding Expectations"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/264150992.md"
description: "Pfizer will announce its third-quarter financial report on November 4, with market expectations for earnings per share at $0.64, a year-on-year decline of 39.6%. Although Pfizer has exceeded expectations for eight consecutive quarters, the downward revision of revenue expectations reflects market concerns about its post-pandemic demand. The stock price has fallen more than 7% this year. Analysts point out that the drug import tariff policy of the Trump administration may drive a rebound in the stock price. The financial report will reveal Pfizer's progress in the field of cancer treatment and the impact of tariff policies on profitability"
datetime: "2025-11-04T07:07:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264150992.md)
  - [en](https://longbridge.com/en/news/264150992.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264150992.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/264150992.md) | [English](https://longbridge.com/en/news/264150992.md)


# Earnings Preview | Pfizer Q3 Reveals TrumpRx Investment Effectiveness Facing Test After Eight Consecutive Quarters of Earnings Exceeding Expectations

According to the Zhitong Finance APP, Pfizer (PFE.US) will announce its third-quarter financial report before the U.S. stock market opens on November 4 (Tuesday). The market expects its earnings per share to reach $0.64, a year-on-year decrease of 39.6%; revenue is expected to be $16.52 billion, a year-on-year decrease of 6.7%. It is worth noting that this pharmaceutical giant has exceeded earnings expectations for eight consecutive quarters, but revenue has only surpassed market expectations in 63% of the quarters.

Recently, analysts have become cautious about Pfizer's outlook—over the past three months, its earnings per share expectations have been downgraded 15 times, and revenue expectations have been downgraded 10 times. This adjustment reflects market concerns about Pfizer's ability to respond to the normalization of demand in the post-pandemic era.

So far this year, Pfizer's stock price has fallen more than 7%, significantly underperforming the market's 16% increase. However, Ockoff Investments, the head of Beyond the Wall Investing, pointed out that due to recent positive news for the company and the Trump administration's three-year suspension of drug import tariffs, Pfizer's stock price is expected to rebound.

Specifically, in late September, Pfizer committed to actively providing four prescription drugs (including the arthritis drug tofacitinib) at discounts of up to 85% through the "Most Favored Nation" pricing platform TrumpRx introduced by Trump, and pledged to invest $70 billion in the U.S. for drug production and research and development in exchange for a three-year tariff exemption.

The upcoming financial report is also expected to reveal Pfizer's progress in the field of cancer treatment and the substantive impact of tariff policies on profitability. In addition, the highly anticipated progress of the Metsera (MTSR.US) acquisition will also be a focus—previously, Novo Nordisk raised its offer to $9 billion (equivalent to $77.75 per share), surpassing Pfizer's $4.9 billion bid

### 相關股票

- [Pfizer (PFE.US)](https://longbridge.com/zh-HK/quote/PFE.US.md)

## 相關資訊與研究

- [Pfizer’s Swedish Ibrance Study: Fresh Real‑World Data Signal for PFE Investors](https://longbridge.com/zh-HK/news/281219504.md)
- [Fosun Pharmaceutical says unit signs GLP-1R licensing agreement with Pfizer](https://longbridge.com/zh-HK/news/269074234.md)
- [Raymond James Financial Earnings Preview: What to Expect](https://longbridge.com/zh-HK/news/281024632.md)
- [Why Pfizer's 2026 guidance miss is 'not a major surprise'](https://longbridge.com/zh-HK/news/269888057.md)
- [(PFE) Pfizer Expects 2026 Adjusted EPS Range $2.80 to $3, vs. FactSet Est of $3.05](https://longbridge.com/zh-HK/news/269859022.md)